The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Brentuximab vedotin in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (Trials in Progress).
 
Nancy L. Bartlett
Consulting or Advisory Role - Acerta Pharma; ADC Therapeutics; BTG; Roche/Genentech; Seagen
Research Funding - ADC Therapeutics (Inst); Affimed Therapeutics (Inst); Autolus (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Forty Seven (Inst); Immune Design (Inst); Janssen (Inst); Kite, a Gilead company (Inst); Merck (Inst); Millennium (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Christopher A. Yasenchak
Stock and Other Ownership Interests - Karyopharm Therapeutics (I)
Honoraria - Seagen; Takeda
Consulting or Advisory Role - BeiGene
Speakers' Bureau - BeiGene
Research Funding - Seagen
 
Khaleel K. Ashraf
No Relationships to Disclose
 
William N. Harwin
Research Funding - Sarah Cannon Research Institute
 
Robert Brownell Sims
Employment - Seagen
Stock and Other Ownership Interests - Seagen
Consulting or Advisory Role - Cellvax
Travel, Accommodations, Expenses - Seagen
 
Grzegorz S. Nowakowski
Consulting or Advisory Role - Celgene (Inst); Debiopharm Group; Genentech (Inst); Kite/Gilead; MorphoSys (Inst); Selvita
Research Funding - Celgene (Inst); MorphoSys (Inst); NanoString Technologies (Inst)